Organisation paid for research Program year 2021 Source: CMS Open Payments

Advanced Clinical Research,Inc

Neither a doctor nor a teaching hospital

Research payments

$436,502

31 payments

Through program year 2021, Advanced Clinical Research,Inc is reported as receiving $436,502 in research payments, across 31 payments.

By program year

3 rows
Year Kind Amount Payments
2021 Research $2,600 2
2020 Research $212,346 17
2019 Research $221,555 12

Breakdown

Who paid Research payments · program years 2019–2021
  1. Sanofi Pasteur Inc. $292,868 23 payments
  2. Sanofi US Services Inc. $143,634 8 payments
Studies the money was for Research payments · program years 2019–2021
  1. A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients with Type 2 Dia $107,324 5 payments
  2. QHD04 Safety and Immunogenicity of Different Dosages of High Dose Quadrivalent Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in Children 6 months to Less than 5 Years of Age $92,126 7 payments
  3. MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalen $76,380 8 payments
  4. MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 $49,281 2 payments
  5. MET59 Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine MCV4 $46,962 4 payments
  6. A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin $21,323 2 payments
  7. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc $14,987 1 payment
  8. CYD51 Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults $14,060 1 payment
  9. CYD51 Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults $14,060 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record